



Ministerie van Volksgezondheid,
Welzijn en Sport

Cost Containment Measures in the Netherlands

Seminar on The Economic Crisis
and Access to Medicines in Europe
Brussels, 16 May 2013

Hugo Hurts


Director, Department of
Pharmaceutical Affairs and Medical
Technology

Ministry of Health, Welfare and Sport,
The Netherlands

Pharmaceutical Market Segmentation

NOVEL THERAPEUTIC CLASSES

OLDER THERAPEUTIC CLASSES



MONOPOLY (first in class)



OLIGOPOLY (single source products only)



COMPETITION: (generic entry)



FULL COMPETITION: (multi source products only)


Pharmaceutical Market: different Segments, different Dynamics, different Policy Approach

NOVEL THERAPEUTIC CLASSES

- Market monopoly – no price competition
- Complex (biological) drugs (e.g. oncology)
- Effective use not yet known / implemented in clinical practice
- Growing expenditure

OLDER THERAPEUTIC CLASSES

- (price) competition
- Less complex drugs
- Effective use known / implemented in clinical practice
- Decreasing expenditure




**Government
Intervention**

**Market
Forces**

- Early conditional access
- Outcome and finance based managed entry arrangements

- Stakeholders promote effective use
- Price competition in market

Total annual outpatient expenditure 2004 – 2012 (x million)



Zonder het toenemende gebruik van dure geneesmiddelen zou er in 2011 sprake zijn geweest van een uitgavendaling.

Bron: Stichting Farmaceutische Kengetallen